Lihui Wang

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

Lihui Wang, Kevin Pearson, Julia E. Ferguson et al. · British Journal of Haematology · 2003 · 146 citations

Medicine, Hematology, Oncology +14

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Claire Lucas, Robert J. Harris, Athina Giannoudis et al. · Haematologica · 2009 · 118 citations · Full text

Life Sciences, Hematology, Oncology +14

Guidelines for the measurement of <i>BCR‐ABL1</i> transcripts in chronic myeloid leukaemia

Letizia Foroni, Gill Wilson, Gareth Gerrard et al. · British Journal of Haematology · 2011 · 105 citations · Full text

Medicine, Hematology, Molecular Biology +17

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas et al. · Blood · 2013 · 93 citations

Medicine, Hematology, Oncology +10